<qa>  What is the name of the endpoints that are used to investigate other efficacy endTo investigate other efficacy endpoints including other microvascular, anatomical, visual acuity change and safety in mild-to-moderate NPDR with DME after intravitreal Ranibizumab injection from baseline through 6 months after treatment. 